FindTrial
Sign In

Cell therapy in patients with COVID-19

Cell therapy in patients with COVID-19 using mesenchymal stem cells

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190717044241N2
Enrollment
5
Registered
2020-04-22
Start date
2020-04-20
Completion date
Unknown
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention group: Patients with COVID-19 who are transplanted with mesenchymal stem cells that are injected 2x 106 (based on IBW) Via (IV) intravenous injection..

Sponsors

Barakat Pharmaceutical Group
Lead Sponsor
Tehran University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
17 Years to 65 Years

Inclusion criteria

Inclusion criteria: Persistent hypoxemia despite receiving less than 93% Saturation oxygen Respiratory failure requires a Ventilator Chest has multilobar infiltrates Shock Organ failure

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Pregnant patient Age less than 17 years Patient with known active malignancy

Design outcomes

Primary

MeasureTime frame
Clinical response. Timepoint: 28 days-From the time of cell injection until the 28th day. Method of measurement: clinical observation by Infectious Diseases Specialist.;O2 saturation. Timepoint: 0,3,6days.Since the injection of the cell. Method of measurement: ventilator.;Inflammation cytokines. Il-6 & Il-10. Timepoint: 0,3,6,14 days-Since the injection of the cell. Method of measurement: Assay by the Elisa.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahshid Saleh - Dr Iman seyhoun

Tehran University of Medical Sciences

Mahshid_saleh@ymail.com+98 21 4305 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 22, 2026